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ChromatinThe steroid receptor coactivator p/CIP, also known as SRC-3, is an oncogene commonly ampliﬁed in breast and
ovarian cancers. p/CIP is known to associate with coactivator arginine methyltransferase 1 (CARM1) on select
estrogen responsive genes. We have shown, using a ChIP-on-chip approach, that in response to stimulation
with 17β-estradiol (E2), the p/CIP/CARM1 complex is recruited to 204 proximal promoters in MCF-7 cells.
Many of the complex target genes have been previously implicated in signaling pathways related to oncogenesis.
Jak2, a member of the Jak/Stat signaling cascade, is one of the direct E2-dependent targets of the p/CIP/CARM1
complex. Following E2-treatment, histonemodiﬁcations at the Jak2 promoter are reﬂective of a transcriptionally
permissive gene, and modest changes in RNA and protein expression lead us to suggest that an additional
factor(s)may be required for amore notable transcriptional and functional response. Bioinformatic examination
of the 204 proximal promoter sequences of p/CIP/CARM1 targets supports the idea that transcription factor
crosstalk is likely the favored mechanism of E2-dependent p/CIP/CARM1 complex recruitment. This data may
have implications towards understanding the oncogenic role of p/CIP in breast cancer and ultimately allow for
the identiﬁcation of new prognostic indicators and/or viable therapeutic targets.
Crown Copyright © 2013 Published by Elsevier B.V. All rights reserved.1. Introduction
Transcriptional activation is a highly dynamic process that involves a
large and diverse class of proteins known as coactivators. Coactivators
mediate speciﬁc transcriptional responses by utilizing several interre-
lated mechanisms involving chromatin remodeling and covalent
modiﬁcation of histones. These mechanisms often work cooperatively
to alter the structural restrictions imposed by packaging DNA into chro-
matin. Additionally, many coactivators function as adaptors/bridging
factors to recruit additional coactivator proteins to target genes [1].
Detailed genome-wide chromatin immunoprecipitation (ChIP) studies
of binding sites for various transcription factors, such as the estrogen
receptor (ER), have provided signiﬁcant insight into the dynamics
of coregulator activity at selected targets [2]. For example, the ER
undergoes a cyclic pattern of association and dissociation at selected
ER targets [2,12], and its association with DNA often coincides with
the recruitment of several ERα-interacting complexes. These complexes
consist of various combinations of coregulators, the basal transcriptional
machinery, as well as RNA polymerase II [3]. The p/300 CBP interacting
protein (p/CIP), also known as SRC3/AIB1/ACTR/RAC3, [4–9] belongs toories, London Regional Cancer
19 685 8692; fax: +1 519 685
13 Published by Elsevier B.V. All riga family of steroid receptor coactivator (SRC) proteins containing two
additional family members (SRC1 and SRC2). p/CIP interacts directly
with the liganded ER, and functions primarily as a bridging factor that
binds tohormone-boundnuclear receptors to promote coactivator com-
plex assembly [10,11]. ChIP assays have established that p/CIP associates
with many endogenous ER target genes in response to 17β-estradiol
(E2), including pS2 [3], cathepsin D [12] and cyclin D1 [13]. Additionally,
p/CIP interacts with other liganded nuclear receptors [5,7–9] and other
classes of transcription factors such as E2F [14] and NFkB [15].
Several studies have shown that p/CIP undergoes a variety of post-
translational modiﬁcations in response to extracellular signals such
as phosphorylation, acetylation, methylation, ubiquitination, and
sumoylation [10,16–20]. These modiﬁcations provide an important
regulatory mechanism that deﬁnes the combinatorial associations
with additional coactivators, resulting in the formation of diverse
multimeric complexes which generate distinct gene expression pro-
grams. The coactivator-associated arginine methyltransferase protein
(CARM1) is one such coactivating partner that interactswith the carboxy
terminus of p/CIP as well as other SRC proteins. CARM1 has been shown
to methylate proteins involved in RNA processing as well as speciﬁc
arginines at positions 17 and 26 on histone H3, suggesting that CARM1
plays a direct role in gene transcription [21,22]. Furthermore, several
studies have demonstrated a correlation between recruitment of
CARM1, methylation of histone H3, and activation of several steroid-
responsive genes [23–26]. Sequential ChIP analysis has identiﬁed ahts reserved.
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genes [16,27,28], and CARM1 synergizes with p/CIP to activate NR-
dependent transcription [29–31]. Collectively, these studies suggest
that direct recruitment of CARM1 by p/CIP represents an essential
activating step for ER-dependent transcription. In the present study,
we have used sequential ChIP–reChIP assays in conjunction with
genome-wide microarray screening to identify E2-dependent gene-
promoter targets of the p/CIP/CARM1 complex. Importantly, our studies
identify the JAK2 promoter as a novel target for the p/CIP/CARM1 com-
plex in response to E2, indicating a novel interplay between ER signaling
and the JAK/STAT pathway at the level of transcription, which may have
implications in ER positive breast cancers where the JAK/STAT signaling
pathway is constitutively active.
2. Results
2.1. Identiﬁcation of genes directly targeted by the p/CIP/CARM1 complex
in response to β-estradiol (E2)
To identify p/CIP/CARM1 target genes which play a role in E2-
dependent signaling we embarked on a genome-wide chromatin
immunoprecipitation assay approach based on DNA Selection and
Ligation (ChIP-DSL) [32]. Brieﬂy, MCF-7 cells were treated with E2
for 45 min and a standard ChIP assaywas performed using an antibody
against p/CIP. The immunoprecipitated material was then reChIPed
using a CARM1-speciﬁc antibody. The resulting p/CIP/CARM1-enriched
and input DNA was then puriﬁed, biotinylated, and combined with
20,000 unique predesigned oligonucleotides. After annealing, the
biotinylated DNA was selected using streptavidin Sepharose and
hybridized to a 20,000 gene promoter array (Fig. 1a). The identiﬁcation
of E2-dependent p/CIP/CARM1 targets was based on the following
criteria: ﬁrst, we established a list of genes displaying a statistically
signiﬁcant enrichment relative to input (pb0.05) regardless of the
treatment. From this list, genes that displayed a 2-fold or greater enrich-
ment in the E2-treated cells relative to control were identiﬁed (i.e. a
twofold or greater enrichment was observed in cells treated with E2
as compared to the untreated cells). The experiment was performed
in triplicate and based on these criteria we identiﬁed 204 gene
promoters that become co-occupied by p/CIP and CARM1 in response
to E2 treatment for 45 min (Fig. 1b–c & Table A1). To validate the
ChIP-DSL analysis, we performed independent ChIP–reChIP experiments
for a random set of target genes identiﬁed (Fig. 2). In the majority of
cases tested, treatment with E2 resulted in the simultaneous recruit-
ment of p/CIP and CARM1, indicating that the false positive rate was
extremely low. It should be emphasized that in our experimental
protocol we have identiﬁed gene targets for p/CIP/CARM1 as a conse-
quence of E2 treatment; which may include genes directly regulated
by the ER, as well as genes indirectly regulated by the ER through its
association with other transcription factors, or via a nongenomic
pathway.
2.2. The ER interacts with a fraction of p/CIP/CARM1 target gene promoters
To better validate our analysis, we compared our results with two
previous studies examining direct E2-dependent ER binding on a
genome-wide scale [33,34]. Carroll et al. discerned 3665 unique E2-
dependent ER binding sites using a ChIP–chip Affymetrix Human
tiling array approach [33], while Welboren et al. used a ChIP-Seq
approach to identify 10,205 genome-wide ER-interaction sites [34].
Using the published chromosomal locations for ER-binding targets
identiﬁed in these studies, we distinguished known genes present
within and/or adjacent to these genomic sites. Next,we conducteddirect
gene-by-gene comparisons of p/CIP/CARM1 targets in our study with
the ER targets identiﬁed in each of the previous studies. An important
consideration for the purposes of this comparison is that while our
analysis was restricted to the 1 kb proximal promoter regions of genes,the studies conducted by both the comparison groups encompassed
binding sites throughout the entire genome. Notably, in each of studies
used for comparative analysis, only a small proportion (4–7%) of ER-
interaction sites were located within promoter regions. Nevertheless,
our analysis indicated that 65/204 (32%) [33] and 118/204 (58%) [34]
(Fig. 3a) of identiﬁed p/CIP/CARM1 complex targets have previously
been shown to display ER binding following E2 treatment. Moreover,
59/204 (29%) p/CIP/CARM1 complex targets were ER binding targets
common to both studies, and were therefore considered to be high con-
ﬁdence ER interactors (Fig. 3b, Table 1).
2.3. Binding site enrichment in the promoters of p/CIP/CARM target gene
promoters
Since our p/CIP/CARM1 target genes may include genes directly
and/or indirectly regulated by the ER, we examined 1 kb upstream
promoter sequences of the gene targets for transcription factor binding
site enrichment, to discern potential mechanisms for E2-dependent
p/CIP/CARM1 binding. Using a candidate scanning approach, we
conducted a search for enrichedmotifswithin our target gene promoter
sequences. Previous studies have shown that in addition to directly
binding ER-binding elements (EREs) in response to ligand, the ER asso-
ciates with C/EBP [35], and can also be targeted to the DNA via interac-
tion with Oct [36,37], Sp1 [38,39] and/or AP-1 [40,41]. Forkhead motifs
were also of interest, as evidence has linked the presence of the FoxA1/
HNF3α motif to ER recruitment [33,42]. When p/CIP/CARM1 target
gene promoter sequences were compared to a background control set
of human housekeeping gene promoters, many enriched putative bind-
ingmotifs were identiﬁed (Table A2). While EREs were shown as being
signiﬁcantly enriched among p/CIP/CARM1 complex promoters, it was
not the most prevalent motif when ranked either by p-value or by
enrichment score. Sp1, C/EBP, Oct, FoxA1, and AP-1 motifs were all
found to be more signiﬁcantly enriched than EREs among the p/CIP/
CARM1 target gene promoters we identiﬁed. Evaluation of these con-
sensus sites within the individual promoter sequences conﬁrmed the
presence and relative abundance of the motifs, with approximately
12% of target promoters containing one or more EREs, 31% C/EBPαmo-
tifs, 24% Sp1, 20% Oct, 10% FoxA1, and 9% contain putative AP-1 sites
(Fig. 3c). Several of the promoters contain consensus sites for more
than one of the considered transcription factors. EREs occurred simulta-
neously more often with C/EBP, Oct, and Sp1 motifs rather than with
FoxA1 or AP-1 motifs (Fig. A1). While a negative correlation between
ERE and AP-1 elements has previously been observed [33], our ﬁndings
are contrary to previous reports [33,42] in that FoxA1motifs did not con-
sistently coincide with the presence of EREs. This discordance is likely
due to our exclusive focus on the proximal promoter, since Kwon et al.
also noted limited association of FoxA1 sites with proximal promoter
ER binding events as identiﬁed byChIP-DSL [43]. The overall enrichment
pattern of putative transcription factor motifs did not change for the 59
p/CIP/CARM1 target genes that are considered to be high conﬁdence ER
binding targets (Fig. A2a) or for targets transcriptionally upregulated
following E2 treatment (Fig. A2b).
Collectively, this analysis demonstrates a consistent pattern of
enriched motifs among p/CIP/CARM1 complex target promoters,
and suggests that transcription factor crosstalk is likely the favored
mechanism of E2-dependent p/CIP/CARM1 recruitment at the proximal
promoters of target genes, regardless of ER binding status or transcrip-
tional state. The presence of EREs suggests that the classical response
with direct binding of the ER is also involved, albeit to a lesser extent.
2.4. A proportion or p/CIP/CARM1 target genes are directly regulated by E2
To correlate p/CIP/CARM1 binding data with the E2-dependent
transcriptional response, we performed gene expression proﬁling
using MCF-7 cells treated with 10 nM E2 for 12 h. RNA was isolated,
reverse transcribed and hybridized to Affymetrix microarrays. A list
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Fig. 1. ChIP-DSL analysis of p/CIP/CARM1 target genes in MCF-7 cells. (A) Sequential ChIP–reChIP coupled to DNA Selection and Ligation (ChIP-DSL) was used to assess global
promoter occupancy by the p/CIP/CARM1 complex. Sequential ChIP–reChIP was performed using either IgG or anti-p/CIP followed by anti-CARM1 antibodies in control and
17β-estradiol stimulated MCF-7 cells. Total input and antibody-enriched DNA were biotinylated and annealed to a 40mer oligonucleotide pool. Annealed oligonucleotides were
selected for with streptavidin-coated metal beads, and appropriate 40mers were ligated to form an 80mer, then labeled and hybridized to the Hu20K array, containing
sequences from 20,000 unique human promoters. Scatter plots of (B) control and (C) 17β-estradiol stimulated p/CIP/CARM1 ChIP (y axis) versus input (x axis) from three
independent biological replicates, demonstrating a normal cluster distribution. (D) Venn diagram depicting the overlap in genes enriched from three independent ChIP-DSL experiments
(Rep 1 to 3).
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was generated (p-valueb0.05 was used as the cutoff). Based on this
criteria, we identiﬁed 396 and 231 genes that were signiﬁcantly
upregulated or downregulated, respectively, following E2-treatment
(Fig. 4a), consistent with previous expression proﬁling studies [43,44].
Comparison of the microarray expression data with the ChIP-DSL
results determined that 33 (16.2%) targets proximally bound by the
p/CIP/CARM1 complex are signiﬁcantly upregulated, and 8 (3.9%)
p/CIP/CARM1 target geneswere downregulated following E2 treatment
(Table 2). The reliability of this analysis was conﬁrmed by quantitative
real-time PCR (qPCR) analysis of selected genes (Fig. 4b). Theseﬁndings
suggests that proximal bindingmaybemore relevant for transcriptionally
upregulated genes, and shows that while the p/CIP/CARM1 complexmayhave a preferential role in transcriptional activation, it also plays a direct
role in the repression of speciﬁc genes.
2.5. The JAK/STAT signaling pathway is a central target for p/CIP/CARM1
Using Ingenuity Pathway Analysis we were also able to identify a
number of networks consisting of target genes that are functionally
or biochemically linked. Several of the genes play a role in disease
(Fig. 5a), and the molecular and cellular functions most associated
with p/CIP/CARM1 target genes have been linked to the initiation
and progression of cancer (Fig. 5b). We found that the network
containing one of the highest number of functionally linked targets
is the canonical JAK/STAT signaling pathway. Several interconnected
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Fig. 2. ChIP analysis of selected direct p/CIP/CARM1 target genes. Control and 17β-estradiol stimulatedMCF-7 cells were cross-linkedwith 1% formaldehyde, and sequential ChIP–reChIP
was performed using either IgG or anti-p/CIP followed by anti-CARM1. RecoveredDNAwas assayed byPCR using primers corresponding to the promoter regions indicated. Selected target
genes shown are pS2, Ccna2, Nfkb1, Dyrk1a, Wbp11, Il15ra, Tgfb1, Nek4, Kras2, and Mapk4.
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including janus tyrosine kinase 2 (Jak2), the interleukin 15 receptor
(Il15ra), and Pias2-a sumo ligase, which functions as a coregulator
for STAT proteins (Fig. 4c, colored targets). Adding to the implied
relevance of p/CIP/CARM1-mediated regulation of this pathway, Stat3
and Stat5 (Fig. 4c, gray targets) were also identiﬁed as E2-dependent
p/CIP/CARM1 binding targets, however, they were not included on the
ﬁnal list as they did not meet the applied statistical criteria. We focused
our initial analysis on the Jak2 gene. JAK2 plays a central role in JAK/
STAT signaling and mammary gland development, and hyperactivation
of this protein is associated with cancer initiation. Importantly, func-
tional ablation of JAK2 in mice protects against the onset of mammary
tumorigenesis [45].2.6. E2-dependent regulation of JAK2
JAK2 expression was assessed using qPCR following E2 treatment of
MCF-7 cells for various time periods. We observed an initial decrease in
Jak2 expression 1 h following E2 treatment, and a gradual increase in
expression thereafter, such that at 12 and 24 h the expression levels
are consistent with preliminary expression array data, with an approxi-
mately 1.5-fold increase in expression when compared to the untreated
control (pb0.05) (Fig. 4b). Analysis of JAK2 protein levels exhibit a
corresponding trend, with a modest increase (~1.3 fold) in protein
expression after 12 and 24 h of E2 stimulation, followed by a decrease
to control unstimulated expression levels at 72 h (Fig. 4d).
To validate recruitment of p/CIP and CARM1 to speciﬁc regions of
the Jak2 promoter we performed ChIP assays. For the purposes of this
analysis, we used a region of the promoter that corresponds to a region
787 to 950 bp upstream of the transcriptional start site (TSS) (Fig. 6a).
An ERE-Sp1 half-site was identiﬁed within this portion of the Jak2
promoter.Cells were treated with E2 for 45 min and promoter occupancy was
assessed by sequential ChIP assay using speciﬁc antibodies recognizing
p/CIP and CARM1. In addition, ChIP assays were performed using an
antibody against the ER to assess a possible mechanism of recruitment
for the p/CIP/CARM1 complex to the Jak2 promoter. We found that
the p/CIP/CARM1 complex binds in a ligand-dependent manner to the
Jak2 promoter (Fig. 6b). Importantly, we also determined that the ER
also binds Jak2 in response to ligand (Fig. 6b). The presence of both
the p/CIP/CARM1 complex and the ER at the same region of the promoter
suggests that E2-dependent complex recruitment to the Jak2 promoter is
mediated through its interaction with the ERE-associated ER. This
ﬁnding is consistent with the putative status of Jak2 as one of the
59 high-conﬁdence ER targets.
To determinewhether the E2-dependent assembly of a p/CIP/CARM1
complex impacts the chromatin marks at the Jak2 promoter, ChIP
analysis was performed using antibodies corresponding to histone
modiﬁcations associated with transcriptional status; histone H3 lysine
4 trimethylation (H3K4me3) and acetylation of histone H3 at Lysines 9
and 14 (H3Ac) aremodiﬁcations generally indicative of transcriptionally
active chromatin structure [46,47]. In addition, CARM1 is known to
asymmetrically dimethylate arginine 17 on histone H3 (H3R17me2), a
mark that is also associated with transcriptional activation [48].
E2-dependent changes in histone modiﬁcations were observed at
the Jak2 promoter. In response to treatment, there was a modest
increase in acetylation of H3K9 and H3K14 (H3K9/14ac) (Fig. 6c) and
a statistically signiﬁcant enrichment in dimethylation of H3R17me
(Fig. 6d), consistent with recruitment of a functional p/CIP/CARM1
complex. Surprisingly, trimethylation of H3K4 remained unchanged
by E2 treatment (Fig. 6c), perhaps suggestive of a transcriptionally per-
missive but not fully active gene state, in agreement with modest
E2-dependent increases in mRNA observed (Fig. 4b).
To determine if the changes in histone modiﬁcations are dependent
on the presence of p/CIP, quantitative ChIP analysis was performed on
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Fig. 3. Binding site enrichment analysis of p/CIP/CARM1 target promoter sequences. (A) Pie charts indicating the proportion of p/CIP/CARM1 target genes that are known to bind the
ER based on comparison with ChIP–chip analysis performed by Carroll et al. (top) and ChIP-Seq analysis performed byWelboren et al. (bottom). (B) Venn diagram showing overlap
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al. 59 p/CIP/CARM1 target genes were common to both the Carroll et al. and Welboren et al. analysis, and were considered to be high conﬁdence ER-binding targets. (C) Bar graph
showing the number of individual p/CIP/CARM1 target promoters that contain ERE, Sp1, AP-1, FoxA1, C/EBP, and Oct binding motifs.
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p/CIP was present minimally on the promoter despite p/CIP depletion
(Fig. 7b), likely due to incomplete knockdown (Fig. 7a). The level of
p/CIP present on the promoter was increased in response to hormone
(Fig. 7b). The functional effect of p/CIP depletion was determined by
ChIP assay evaluating the presence of the CARM1-dependent histone
modiﬁcation H3R17me2 in response to E2. As a chromatinmark associ-
ated with transcriptional activation, in the absence of p/CIP [and
complex] recruitment, E2-dependent dimethylation of R17 on histone
H3 was reduced (Fig. 7b), indicating that p/CIP is likely required for
recruitment of CARM1, and its subsequent methyltransferase activity.
To further our understanding of the role that the p/CIP/CARM1
complex plays in regulating Jak2, we assessed its E2-dependent ex-
pression in the absence of p/CIP or CARM1. When a control siRNA was
used, we saw a statistically signiﬁcant induction of Jak2 expression,
based on realtime PCR, after 12 and 24 h of E2 treatment. However,
when p/CIPwas downregulated using siRNA, this effect was diminished
(Fig. 7c). A similar experimentwas performed following CARM1 knock-
down and, although the knockdown was not complete, there was amore dramatic loss of E2-dependent Jak2 expression as compared to
p/CIP knockdown (Fig. 7d). Interestingly, when MCF7 cells were treated
with E2, we also observed an increase in Stat3 phosphorylation,
indicative of E2-dependent JAK/STAT pathway activation. However,
when either p/CIP or CARM1 was depleted, this effect was lost
(Fig. 7c–d). Collectively, this data suggests that p/CIP and CARM1 are
in part required for the E2-dependent regulation of Jak2 transcription
and activation of the JAK/STAT signaling pathway in MCF7 cells.
3. Discussion
In the present study, we identiﬁed E2-dependent target genes for
the p/CIP/CARM1 coregulatory complex. We then determined the
transcriptional status of those genes following 12 h E2 treatment,
and compared the lists with known ER binding sites in an attempt to
clarify a mechanism for complex recruitment and subsequent gene
regulation.
Global characterization of p/CIP (SRC-3) binding sites conducted by
Lanz et al. identiﬁed 12,294 E2-dependent targets using ChIP-Seq, 5512
Table 1
p/CIP/CARM1 target genes bind the ER.
Gene ID Accession number Description
TLR3 NM_003265 Transmembrane receptor
DBC1 NM_014618 Peptidase
LAP3 NM_015907 Peptidase
CLDN12 NM_012129 Calcium-independent cell–cell adhesion
SLC4A5 NM_021196 Solute carrier family 4, sodium bicarbonate cotransporter, member 5
PTER NM_030664 Phosphotriesterase related
TRAF3 NM_003300 TNF receptor-associated factor 3/apoptosis
LETM1 NM_012318 Leucine zipper-EF-hand containing transmembrane protein 1
IGSF4/CADM1 NM_014333 Cell adhesion molecule 1/tumor suppressor
OCA2 NM_000275 Oculocutaneous albinism II
SLC26A1 NM_022042 Solute carrier family 26 (sulfate transporter), member 1
FRMD1 NM_024919 FERM domain containing 1
N4BP1 NM_153029 NEDD4 binding protein 1
CTNND1 NM_001331 Catenin (cadherin-associated protein), delta 1
CDH7 NM_033646 Cadherin 7, type 2
RAD9B NM_152442 RAD9 homolog B (S. cerevisiae)/DNA replication
ECT2 NM_018098 Epithelial cell transforming sequence 2 oncogene
PCSK5 NM_006200 Proprotein convertase subtilisin/kexin type 5
GATM NM_001482 Glycine amidinotransferase (L-arginine:glycine amidinotransferase)
TUBGCP6 NM_020461 Tubulin, gamma complex associated protein 6
KCTD16 XM_098368 Potassium channel tetramerization domain containing 16
TGFB1 NM_000660 Growth factor
NEK4 NM_003157 Enzyme
RPS4X NM_001007 Ribosomal protein S4, X-linked
STARD4 NM_139164 StAR-related lipid transfer (START) domain containing 4
HRASLS NM_020386 HRAS-like suppressor
PKP4 NM_003628 Plakophilin 4/cell adhesion
SMARCAL1 NM_014140 SWI/SNF related, matrix associated, regulator of chromatin, a-like 1
CD9 NM_001769 CD9 molecule/cell adhesion
C9orf95 NM_017881 Orf
TMEM16F XM_113743 Transmembrane protein 16 F
IVNS1ABP NM_006469 Inﬂuenza virus NS1A binding protein
DDX54 NM_024072 DEAD (Asp-Glu-Ala-Asp) box polypeptide 54/transcriptional regulator
ITPKB NM_002221 Inositol 1,4,5-trisphosphate 3-kinase B
POLR2F NM_021974 Polymerase (RNA) II (DNA directed) polypeptide F
LAMA1 NM_005559 Laminin, alpha 1/cell adhesion protein
TSHB NM_000549 Thyroid stimulating hormone, beta
RDH10 NM_172037 Retinol dehydrogenase 10 (all-trans)
KCNQ1 NM_000218 Potassium voltage-gated channel, KQT-like subfamily, member 1
KCTD3 NM_016121 Potassium channel tetramerization domain containing 3
PCP4 NM_006198 Purkinje cell protein 4
LRFN4 NM_024036 Leucine rich repeat and ﬁbronectin type III domain containing 4
ABAT NM_000663 4-aminobutyrate aminotransferase
PTPRJ NM_002843 Protein tyrosine phosphatase, receptor type, J
JAK2 NM_004972 Janus kinase 2 (a protein tyrosine kinase)
GPR132 NM_013345 G protein-coupled receptor 132
HARS NM_002109 Histidyl-tRNA synthetase
MDS009 NM_020234 DTWD1 DTW domain containing 1
POLG NM_002693 Polymerase (DNA directed), gamma
HSD17B12 NM_016142 Hydroxysteroid (17-beta) dehydrogenase 12
AKAP13 NM_006738 A kinase (PRKA) anchor protein 13
DPYS NM_001385 Dihydropyrimidinase
DYRK1A NM_101395 Dual-speciﬁcity tyrosine-(Y)-phosphorylation regulated kinase 1A
EDC3 NM_025083 Homo sapiens enhancer of mRNA decapping 3 homolog (S. cerevisiae)
SLC39A10 XM_047707 Solute carrier family 39 (zinc transporter), member 10
SAMD3 NM_152552 Sterile alpha motif domain containing 3
FLRT2 NM_013231 Fibronectin leucine rich transmembrane protein 2/cell adhesion
MGC14156 NM_032906 PIGY phosphatidylinositol glycan anchor biosynthesis, class Y
MXD3 NM_031300 MAX dimerization protein 3
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Many of these sites overlap with previously identiﬁed ER binding
regions, and, in accordance with accumulating genomic analysis indi-
cating that the majority of ER binding sites are located in regions far
upstreamof the TSS, only aminority (~3%) of E2-dependent p/CIP bind-
ing is suggested to occur within 500 bp of the TSS. The level of CARM1
activity (as assayed by its methylation of H3R17 and/or p/CIP) across
the genome also appears to cluster predominantly at a distance from
promoters [50]. These observations of a limited set of proximal promoter
binding sites for p/CIP, and minimal CARM1 methylation activity at
promoter elements correspond with the relatively small number of
promoters we identiﬁed as interacting with the p/CIP/CARM1 complex,and is also consistent with proximal ER binding events previously iden-
tiﬁed using the 1 kb promoter-speciﬁc ChIP-DSL approach [43].
Although now largely superseded by ChiP-Seq, ChIP-DSL is a highly
sensitive assay which eliminates some of the biases introduced by
more conventional ChIP-on-chip whole-genome approaches. In ChIP-
DSL, the immunoprecipitated genomic DNA is used only as a template
to mediate annealing and ligation of aligned oligonucleotide pairs.
After annealing, the biotinylated DNA is then selected using streptavidin
Sepharose and Taq ligase is used to ligate oligonucleotides positioned
directly adjacent to each other, creating complete amplicons which are
hybridized to a 20,000 gene promoter array. A limitation of this
approach is that analysis is restricted to those promoters found on the
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Fig. 4. p/CIP/CARM1 target genes are directly regulated by E2. (A) Differentially expressed genes after E2-stimulation relative to unstimulated control cells. (B) Realtime RT-PCR
analysis of pS2, Jak2, and Mapk4 following stimulation of MCF-7 cells with 17β-estradiol for 1 h, 3 h, 12 h, and 24 h. Data is expressed as means and standard error of the mean
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untreated samples are indicated. (C) Canonical pathway diagram, highlighting statistically signiﬁcant p/CIP/CARM1 complex direct targets in color. Targets in gray are bound by
p/CIP/CARM1 but do not meet statistical criteria. (D) Western blot showing JAK2 levels in MCF7 cells following 17β-estradiol stimulation of MCF7 cells for 1, 3, 12, 24, 48, and
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shown that the majority of ER binding sites are found more distal than
the proximal promoter. Nevertheless, promoter proximal interactions
do occur in response to E2 and this interaction can have transcriptional
consequences. Furthermore, our study does not examine ER binding
directly, but rather focuses on occupancy of p/CIP/CARM1 in response
to E2. Thus, it would theoretically include those targets that are targeted
to promoter regions by E2 independent of direct DNA binding, and
possibly via enhancer–promoter interactions.
A major advantage of this approach is that we identiﬁed 204
promoter-proximal interaction sites for the p/CIP/CARM1 complex,
eliminating the complicated process of assigning responsive genes to
distant binding sites, and insteadwere able to directly correlate complex
interaction with transcriptional effect. Previous microarray studies with
E2-stimulation can be broadly categorized based on the length of
hormone treatment. There is an observable difference in the pattern of
expression change, such that at early time points (b6 h) more genes
are upregulated and more variation is evident between time points,
while at later time points (>12 h) there is a more stable pattern of
expression change and the majority of genes are downregulated
[33,44]. We showed that after 12 h of stimulation with E2, 20% of
p/CIP/CARM1 complex target genes identiﬁed by ChIP-DSL were tran-
scriptionally altered (16.2% upregulated and 3.9% downregulated). Therelatively small number of transcriptionally changed target genes after
12 h implies that proximal recruitment of the p/CIP/CARM1 complex
is not predictive of E2-dependent gene expression at this late time
point. However, among those targets that are transcriptionally altered,
the complex plays a preferential role in activation, consistent with the
role of p/CIP as a coactivator. While the changes in target gene expres-
sion that we observed were modest, we do observe notable changes in
chromatin modiﬁcations, suggesting that E2 may facilitate crosstalk.
Direct comparison of target gene promoters in our study with
known genomic ER binding sites in MCF-7 cells [under equivalent E2-
stimulation conditions] [33,34] identiﬁed 59/204 (29%) p/CIP/CARM1
complex targets as putative high-conﬁdence ER binding targets. There-
fore, it seems likely that the p/CIP/CARM1 complex is recruited to this
subset of E2-responsive promoters via the ER. We also identiﬁed a
trend in which binding motifs for transcription factors known to facili-
tate ER recruitmentwere enriched among p/CIP/CARM1 complex target
promoter sequences. While Sp1, C/EBP, Oct, FoxA1, and AP-1 motifs
have previously been shown to be enriched, in addition to EREs, in the
sequences surrounding ER binding events on a genome-wide scale
[33,42,50], there has not previously been much discussion related to
the proximal promoter region or when considering recruitment of an
E2-regulated complex. Neither the predicted ER-binding state nor the
transcriptional status of complex target genes after 12 h E2 treatment
Table 2
Genes directly regulated by the p/CIP/CARM1 complexa.
Gene ID Accession
number
Description
Genes activated by E2
NFKB1 NM_003998 Nuclear factor of kappa light polypeptide gene enhancer
MOCOS NM_017947 Enzyme
JAK2 NM_004972 Janus kinase 2 (a protein tyrosine kinase)
STARD4 NM_139164 StAR-related lipid transfer (START) domain containing 4
HARS NM_002109 Histidyl-tRNA synthetase
IGSF4/
CADM1
NM_014333 Cell adhesion molecule 1/tumor suppressor
KCTD3 NM_016121 Potassium channel tetramerization domain containing 3
GTF2E2 NM_002095 General transcription factor IIE, polypeptide 2, beta
34 kDa
ZIM3 NM_052882 Zinc ﬁnger, imprinted 3/transcription factor
PDCD8 NM_004208 Enzyme/cell death
WBP11 NM_016312 WW domain binding protein 11
PRKRIR NM_004705 Protein-kinase, interferon-inducible RNA dependent
inhibitor
ZNF567 NM_152603 Transcription factor
IVNS1ABP NM_006469 Inﬂuenza virus NS1A binding protein
BMI1 NM_005180 BMI1 polycomb ring ﬁnger oncogene
M6PR NM_002355 Mannose-6-phosphate receptor (cation dependent)
HSD17B12 NM_016142 Hydroxysteroid (17-beta) dehydrogenase 12
TM4SF8 NM_005724 Tetraspanin 3
CCNA2 NM_001237 Cyclin A2/cell cycle
LAP3 NM_015907 Peptidase
POLR2F NM_021974 Polymerase (RNA) II (DNA directed) polypeptide F
RAD9B NM_152442 RAD9 homolog B (S. cerevisiae)/DNA replication
DYRK1A NM_101395 Dual-speciﬁcity tyrosine(Y)-phosphorylation
regulated kinase 1A
PCNA NM_002592 Proliferating cell nuclear antigen
PCP4 NM_006198 Purkinje cell protein 4
ZNF800 NM_176814 Unknown
PELO NM_015946 Pelota homolog (Drosophila)
DPH2L2 NM_001384 DPH2 homolog (S. cerevisiae)
RFXAP NM_000538 Regulatory factor X-associated protein
CLDN12 NM_012129 Calcium-independent cell–cell adhesion
PIAS2 NM_004671 Protein inhibitor of activated STAT, 2
ELAC1 NM_018696 ElaC homolog 1 (E. coli)/trna processing
RDH10 NM_172037 Retinol dehydrogenase 10 (all-trans)
Genes repressed by E2
PXMP4 NM_007238 Peroxisomal membrane protein 4, 24 kDa
HBD NM_000519 Hemoglobin, beta///hemoglobin, delta
MAPK4 NM_002747 Mitogen-activated protein kinase 4
ITPKB NM_002221 Inositol 1,4,5-trisphosphate 3-kinase B
MXD3 NM_031300 MAX dimerization protein 3
MGC15882 NM_032884 C1orf94
LMOD1 NM_012134 Leiomodin 1 (smooth muscle)
CD9 NM_001769 CD9 molecule/cell adhesion
a Comparative analysis of ChIP–chip data and expression analysis following 12 h
E2-stimulation of MCF-7 cells allowed for the identiﬁcation of p/CIP/CARM1 regulated
genes.
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studied, and so, consensus mechanisms for differential transcriptional
responses as implied by the recruitment of the ER could not be inferred.
Several of the targets identiﬁed are components of the canonical
JAK/STAT signaling pathway. This pathway mediates the activity of a
wide variety of cytokines and growth factors [51]. JAK2 is a central
component of the pathway and is responsible for phosphorylation
and activation of the STAT family of proteins, which normally reside
in the cytoplasm and, upon activation, translocate to the nucleus and
bind to speciﬁc target genes involved in cell proliferation and survival
[51]. JAK2 or STAT5 null mice display phenotypes remarkably simi-
lar to the ERα and p/CIP knockout animals including defects in
mammary gland cell proliferation and apoptosis [52,53]. Importantly,
overexpression or constitutive activation of STAT3 and 5 proteins has
been described in many types of cancers [54] and promote the occur-
rence of sporadic mammary cancers inmice [45,55–57]. In proliferating
ER-positive tumor cells, E2 is known to stimulate phosphorylation and
activation of STAT3 and 5, although the mechanism has not been fullyelucidated [58–60]. The PIAS family, most notably recognized for their
role as coregulators for STAT proteins, is also of interest as PIAS1 has
been shown to sumoylate p/CIP [and other SRCs], affecting activity
and stability in steroid-receptor signaling pathways in MCF7 cells [20].
Collectively, these ﬁndings suggest that ER signaling and the JAK/STAT
pathway may cooperate in the regulation of mechanisms implicated
in mammary cancers. This cooperation may be mediated, at least in
part, through the p/CIP/CARM1 complex.
We observed recruitment of the p/CIP/CARM1 complex to the 1 kb
promoter of Jak2 in response to E2, with a transcriptional upregulation
after 12 and 24 h, but no signiﬁcant effect on protein levels with E2
stimulation. Analysis of histonemodiﬁcations to the proximal 1 kb pro-
moter revealed an unclear pattern that was predictive neither of tran-
scriptional activation nor repression. A modest increase in acetylation
of histone H3 at K9 and K14 at a region approximately 1 kb upstream
of the Jak2 TSS in response to E2, which coincides with p/CIP/CARM1
complex recruitment, suggestive of a transcriptionally active gene. In
contrast, therewas a lack of discernible change in H3K4me3 in response
to E2 at the same promoter region, a modiﬁcation that would be
expected to be present near the TSS of an actively transcribed gene
[61,62]. We suggest that these changes reﬂect a promoter that is not
necessarily in line with a fully transcriptionally active state but may
instead be permissive, poised for more robust transcriptional activa-
tion, in a process that may require additional signals.
Our study of chromatin modiﬁcations was focused to a single time
point for E2 treatment. This is based on previous studies showing max-
imal p/CIP/CARM1 recruitment to the pS2 promoter 45 min after the
addition of hormone [16]. Importantly, a statistically signiﬁcant E2-
dependent increase in H3R17me2 was evident, corresponding with
the region of p/CIP/CARM1 recruitment, suggesting the complex is
functional on the Jak2 promoter. Reinforcing this idea, we noted that
following depletion of p/CIP, E2-dependent H3R17me2 of the Jak2
promoter was greatly reduced in addition to an observable loss of
p/CIP recruitment. Finally, siRNA mediated depletion of p/CIP resulted
in a reduction in E2-induced transcription of Jak2, with residual E2-
responsiveness likely due to functional redundancy between SRC family
members. However, depletion of CARM1 caused amore dramatic loss in
E2-dependent Jak2 transcription, suggesting that its enzymatic activity
is in fact important for the observed regulation by the p/CIP/CARM1
complex. CARM1 activity has previously been associated with the regu-
lation of a subset of the ER cistrome [50], and herein we provide a
speciﬁc example of its E2-dependent recruitment, as part of an active
coregulatory complex, to the Jak2 promoter. We also observed an
increase in phosphorylated STAT3, indicative of activation of the JAK/
STAT signaling pathway. While this activation is not necessarily depen-
dent on Jak2 transcriptional upregulation, this effect was lost following
siRNA-mediated silencing of p/CIP or CARM1.
Collectively,while the changes in E2-dependentH3R17 dimethylation
are indicative of active Jak2 transcription, the other chromatin marks
we examined, as well as the modest response at the RNA and protein
levels, were inconsistent with a fully transcriptionally active pro-
moter. We suggest that an additional signal may be required for a
more robust transcriptional response of the Jak2 gene. In addition,
despite the changes in expression of select genes, the majority of
complex targets did not exhibit a widespread transcriptional re-
sponse to 12 h E2 treatment, ultimately suggesting that E2 may
cause a general “rewiring” of speciﬁc signaling pathways, through
recruitment of the p/CIP/CARM1 complex, so that many essential
genes become “poised” for transcription.
4. Materials and methods
4.1. Plasmids, antibodies, and reagents
A complete list of primers used can be found in Table A3 of the
supplemental material. Antibodies used in this study are listed in
A B
Fig. 5. Functional classiﬁcation of p/CIP/CARM1 target gene promoters. (A) Schematic Ingenuity Pathway Analysis indicates (A) that cancer is one of the diseases most commonly
associated with the p/CIP/CARM1 target genes and (B) that molecular and cellular functions associated with the gene set highlight cellular growth and proliferation as
predominating.
Adapted from © 2000–2011 Ingenuity Systems, Inc. All rights reserved.
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these studies are commercial antibodies, with the exception of the
p/CIP antibody. The method by which this antibody was generated,
puriﬁed, and tested has been previously described [4]. 17β-Estradiol
(water soluble) was purchased fromWisent. All siRNA used was pur-
chased from Dharmacon.0
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Fig. 7. p/CIP/CARM1 mediated E2-dependent regulation of Jak2. (A) Representative Western blot showing 72 h siRNA depletion of p/CIP in MCF7 cells. (B) ChIPs were performed in
triplicate at Jak2 promoter regions using indicated antibodies, quantitated by real-time PCR, normalized to IgG control and shown as a percentage of Input. Data is expressed as
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treatment.
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inhibitor cocktail. Extracts were centrifuged for 10 min at 14,000 rpm
at 4 °C and the soluble fractions were retained. Samples were nor-
malized for protein content and were separated by SDS-PAGE, trans-
ferred to nitrocellulose or PVDF membrane and blocked overnight in
PBS containing 0.1% TWEEN-20 and 5% nonfat dried milk. The appro-
priate antibodies were then diluted in blocking buffer and the mem-
brane was probed for 2 h at room temperature with rocking,
followed by incubation with secondary antibody for 1 h. Proteins
were detected using ECL according to the manufacturer's recom-
mendations (Amersham).
4.3. RNA isolation and real-time PCR
Total cellular RNA was isolated using RNeasy kit (Qiagen). The
quality and quantity of RNA were evaluated by measuring OD 260/
280. For real-time PCR analysis, 0.2 μg of RNA was reverse-transcribed
with TaqMan reverse transcriptase (Applied Biosystems) using randomhexamers to generate cDNA. All amplicons were detected using the 5′
nuclease (Taqman) assay with 5′ labeled probes. Probes were already
predesigned and quality tested (Applied Biosystems). Reactions were
performed according to the manufacturer's recommendations (Applied
Biosystems) andwere run in replicates of two, in a 96-well format. Each
reaction included 18S RNA as a control for normalization, and reactions
lacking cDNA served as negative controls. Two independent experi-
ments were performed for each gene following treatment with E2,
and a mean value was obtained and compared to the mean expression
level of each gene from untreated cells. Applied Biosystems 7500 Real
Time PCR System software was used to identify cycle threshold (Ct)
for each reaction.
4.4. RNA microarray analysis
Total RNA was extracted from MCF-7 cells treated with 10 nM E2
for 12 h and from control, untreated cells. Independent biological
triplicates were performed for each treatment, including control
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and hybridized to HgU133A+2 human affymetrix DNA microarray.
Hybridization, washing, scanning and analysis of genechips were
performed at the University of Western Ontario, London Regional
Genomics Centre (London, Ontario, Canada).
An average intensity of each E2-treated samplewas compared to the
average intensity for control non-treated samples. Three biological rep-
licates for each array were processed and the data was transformed
using Robust Multi-Array normalization (5) and values below 0.01
were set to 0.01. Each measurement was normalized by dividing all
measurements in that sample by the 50th percentile. Ratios were then
calculated for all samples against the median of the control samples. A
student t-test statistical analysis was conducted and false positives
were reduced using Benjamini and Hochberg false discovery rate.
4.5. Chromatin immunoprecipitation assay
MCF-7 cells were cross-linked with 1% formaldehyde at room
temperature for 5 min. Cross-linking was quenched by immediately
washing cells twice with ice-cold PBS and harvesting in PBS containing
PMSF. Cell pellets were lysed in 0.2 ml of cell lysis buffer (50 mM Tris–
HCl [pH 8.1], 10 mM EDTA, 1% SDS, and protease inhibitors) and incu-
bated on ice for 10 min. Lysates were sonicated to yield DNA fragments
ranging in size from 300- to 1000-bp. Approximately 450 μg of the
cross-linked, sheared chromatin solution was used for immunoprecipi-
tation. A small portion of each IPwas saved as input DNA (5%). Superna-
tants were diluted 10-fold in dilution buffer (20 mM Tris–HCl [pH 8.1],
1% Triton X-100, 2 mM EDTA, 150 mM NaCl, and protease inhibitors)
and immunoprecipitated using a protein A-Sepharose slurry or with
MagnaChIP Protein A magnetic beads.
When using the Protein A-Sepharose slurry, lysates were precleared
with 50 μl of 50% slurry protein A-Sepharose containing 2.5 μg of
sheared salmon sperm DNA for 2 h at 4 °C. Immunoprecipitation was
performed overnight at 4 °C with 1.5–4 μg of the antibodies. 50 μl of
protein A-Sepharose containing 2.5 μg of salmon sperm DNA per ml
was added to the solution and incubated for 1 h at 4 °C. Magnetic
beads were washed using PBS with 0.1% Tween-20, incubated with
the relevant antibodies for 2.5 h at 4 °C, and rewashed prior to immu-
noprecipitation overnight at 4 °C. The beads were washed one time
each with wash buffer I (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
20 mM Tris–HCl, 150 mM NaCl), wash buffer II (0.1% SDS, 1% Triton
X-100, 2 mM EDTA, 20 mM Tris–HCl, 500 mM NaCl), wash buffer III
(0.25 M LiCl; 1% NP-40; 1% Na-Deoxycholate; 1 mM EDTA; 10 mM
TrisHCl) and twice with TE buffer. Immunoprecipitated material
was extracted twice with 150 μl elution buffer (1% SDS-0.1 M
NaHCO3). If sequential ChIP was conducted, eluted samples were re-
immunoprecipitated overnight at 4 °C with 1.5–4 μg of secondary anti-
bodies.Washes and elution steps were repeated. NaCl was added to the
ﬁnal 150 μl eluate to a concentration of 200 mM and the cross-linking
was reversed by heating at 65 °C overnight. DNA was puriﬁed using
Qiagen PCR puriﬁcation spin columns.
For analysis by conventional PCR, conditions were as follows: initial
denaturing cycle of at 94 °C for 3 min, followed by 40 cycles of 94 °C for
30 s, ~57 °C for 30 s and 72 °C for 45 s, and a ﬁnal elongation step of
72 °C for 10 min. For experiments involving E2-stimulation, MCF-7
cells were plated to approximately 90% conﬂuence and treated with
10−7 M E2 for 45 min prior to ChIP analysis.
For some experiments, DNA isolated from ChIP experiments was
subjected to quantitation by real time PCR using Brilliant SYBR
green master mix (Stratagene; 600548). Primers were identiﬁed
using the Primer Express program (Stratagene) and tested to establish
optimum reaction conditions. Reactions were performed in a 25 μl
volume according to manufacturer's recommendations. The reaction
was carried out and measured using Mx3000P realtime instrument.
Standard curves were generated using total input DNA (copy number
range: 8×105 to 8×101). The IP and IgG DNA copy number wascalculated by extrapolating their respective Ct value from the standard
curve. The nonimmune IgG copy number was subtracted from IP DNA
copy number. The resulting IP copy number was initially normalized
against the total input DNA by dividing the IP by input. The average
copy number with E2-treated IPs was then normalized to untreated
control IPs, and recruitment represented as a fold-change with E2-
treatment. All measurements were done in duplicate and an average
Ct valuewas used to calculate copy number. Two independent realtime
reactions were done for each experiment.
4.6. ChIP-DSL assay
Chromatin immunoprecipitation coupled to DNA selection and
Ligation (ChIP-DSL) was used to assess global promoter occupancy
by p/CIP/CARM1. MCF-7 cells were cross-linked with formaldehyde
and subjected to standard sequential ChIP–reChIP assay using afﬁnity
puriﬁed anti-p/CIP and anti-CARM1 antibodies. The procedure for
oligonucleotide annealing, solid phase selection ligation and PCR
ampliﬁcation were performed exactly as described (Aviva Systems
Biology; H20K, Cat# AK-0504). The antibody-enriched DNA and the
total input were biotinylated followed by annealing to the 40mer
oligonucleotide pool. The DNA–oligonucleotide complexes are then
selected by binding to streptavidin-conjugated magnetic beads, while
the non-annealed oligonucleotides are washed away. Correctly paired
40mers are then ligated to form the corresponding 80mer which is
ﬂanked by both universal primer annealing sites (T3 and T7) giving
rise to a complete amplicon. A PCR reaction was then conducted on
the amplicons using ﬂuorescently labeled T7 and regular T3 primers.
Total input DNAwas PCR ampliﬁed using Cy5 (green) labeled T7 primer
and the immunoprecipitated (IP) samplewas ampliﬁed using Cy3 (red)
labeled T7 primer. The PCR products are co-hybridized to the 40mer
array (Hu20K) to derive an enrichment ratio for each target. After
hybridization and washing, array slides were scanned on a One Virtek
(Bio-Rad) Chip Reader, and the ArrayVision (v6.0) software package
(London Regional Genomics Centre, London, Ontario, Canada) was
used to quantify ﬂuorescence intensity. The Chip on chip intensity
values were normalized using a Lowess curve, which was ﬁt to the log
intensity versus log-ratio plot and 20% of the data was used to calculate
the Lowess ﬁt at each point. Following normalization, a two-sided
student's t-test was conducted where standard deviation of the repli-
cates was used to calculate a p-value. Fold change was calculated for
each gene using a mean value that was calculated from all three biolog-
ical replicates.
4.7. Ingenuity Pathway Analysis
Ingenuity Pathways Systems (http://www.ingenuity.com) analysis
was employed to group statistically signiﬁcant genes. The 204 genes
that bound p/CIP/CARM1 directly and were transcriptionally affected
by E2 were considered for Functional Analysis to identify the biological
functions and/or diseases that were most signiﬁcant to the data set. A
right‐tailed Fisher's exact testwas used to calculate a p‐value determin-
ing the probability that each biological function and/or disease assigned
to that data set is due to chance alone.
4.8. Promoter enrichment analysis
Promoter sequences were identiﬁed using Gene2Promoter within
the Genomatix Suite (www.genomatix.de). Input was in the form of
gene accession numbers, and comparison with transcripts that have
been mapped to the ElDorado genome yielded mapped sequence
results and extracted promoters. A deﬁned 1000 bp upstream of the
mapped transcriptional start sites were selected for further transcrip-
tion factor binding site analysis. To search for enriched consenus motifs
within ElDorado extracted promoter sequences the BIOBASE Knowl-
edge Librarywas used, making use ofMATCH software and the Transfac
1474 N. Coughlan et al. / Biochimica et Biophysica Acta 1833 (2013) 1463–1475database. Searches were performed with the best supported promoters
using the vertebrate non redundant (minFP) proﬁle. Background
frequencies were determined using control set of human housekeeping
gene promoters. Optimizedmatrix cutoffs and searchwindowpositions
were used. Signiﬁcant matrices were found with p-valueb0.001 and
Yes/No>1.2.
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